Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

Bella Pajares; Marina Pollán; Miguel Martín; John R. Mackey; Aňa Lluch; Joaquín Gavilá; Charles L. Vogel; Manuel Ruíz‐Borrego; Lourdes Calvo; Tadeusz Pieńkowski; Álvaro Rodríguez-Lescure; Miguel Ángel Seguí; Olivier Trédan; Antonio Antón; Manuel Ramos; María del Carmen Cámara; César Rodríguez-Martín; Eva Carrasco; Emilio Alba

doi:10.1186/bcr3572

Abstract

Severely obese patients treated with anthracyclines and taxanes present a worse prognosis regarding recurrence, BCM, and OM than patients with BMI < 25. The magnitude of the harmful effect of BMI on survival-related outcomes was similar across subtypes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pajares et al. (2013) studied this question.

synapsesocial.com/papers/69d82da0617ce96c42ae31a7 https://doi.org/10.1186/bcr3572

View Full Paper

Ask AI

Bookmark

Share

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

Abstract

Discussion

Cite This Study

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

Abstract

Discussion

Cite This Study

Keep reading

More from Breast Cancer Research

Keep reading

More from Breast Cancer Research